This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Conflict of Interest  • Rheumatology  • Musculoskeletal Syndromes (Chronic Fatigue, Gulf War)  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Joseph D. Piorkowski, Jr, DO, JD, MPH

JAMA. 2004;292:2655-2657. Published online November 22, 2004 (doi:10.1001/jama.292.21.2655)

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

JAMA has invited this response from Bayer Corporation to the article authored by Psaty et al (the "Article"), which appears on page 2622 in this issue. Although the Article is presented as a scientific review of facts, sections are copied verbatim from a report submitted by the lead author in a US lawsuit in which he served as a paid expert for the plaintiff. Moreover, the Article’s conclusions are based upon selected exhibits from another lawsuit in which another author (Dr Ray) submitted a report for plaintiffs. Bayer won that court case (as well as the only other cerivastatin cases that have gone to trial). At least 2 of the authors continue to participate in lawsuits against Bayer.

This response presents a more complete picture of the information available in the public record. It is submitted on Bayer’s behalf by one of its . . . [Full Text of this Article]

Background

Errors of the Article

Conclusion

AUTHOR INFORMATION



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs
David J. Graham, Judy A. Staffa, Deborah Shatin, Susan E. Andrade, Stephanie D. Schech, Lois La Grenade, Jerry H. Gurwitz, K. Arnold Chan, Michael J. Goodman, and Richard Platt
JAMA. 2004;292(21):2585-2590.
ABSTRACT | FULL TEXT  

Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis
Bruce M. Psaty, Curt D. Furberg, Wayne A. Ray, and Noel S. Weiss
JAMA. 2004;292(21):2622-2631.
ABSTRACT | FULL TEXT  

Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: A Counterpoint
Brian L. Strom
JAMA. 2004;292(21):2643-2646.
EXTRACT | FULL TEXT  

Postmarketing Surveillance—Lack of Vigilance, Lack of Trust
Phil B. Fontanarosa, Drummond Rennie, and Catherine D. DeAngelis
JAMA. 2004;292(21):2647-2650.
EXTRACT | FULL TEXT  

Authors’ Reply to Bayer’s Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis"
Bruce M. Psaty, Curt D. Furberg, Wayne A. Ray, and Noel S. Weiss
JAMA. 2004;292(21):2658-2659.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Statin-Induced Myopathy: The Two Faces of Janus
Arora et al.
J CARDIOVASC PHARMACOL THER 2006;11:105-112.
ABSTRACT  

Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects
Rief et al.
Arch Intern Med 2006;166:155-160.
ABSTRACT | FULL TEXT  

Post-Marketing Drug Safety: Keep Patients Your Priority
Dugdale
DOC News 2005;2:3-3.
FULL TEXT  

Statins and Rhabdomyolysis -- Clinical Data, Health Policy, and Politics
JWatch General 2005;2005:2-2.
FULL TEXT  

Postmarketing Surveillance--Lack of Vigilance, Lack of Trust
Fontanarosa et al.
JAMA 2004;292:2647-2650.
FULL TEXT